<DOC>
	<DOC>NCT03071198</DOC>
	<brief_summary>Clinical effect of neoadjuvant hierarchical treatment based on chemotherapy for T3-4N0-2M0 middle and lower rectal cancer</brief_summary>
	<brief_title>Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy</brief_title>
	<detailed_description>By setting 3-Year disease-free survival (DFS) as main objective, the treatment strategy will be optimizing as neoadjuvant chemotherapy alone and chemo-radio-chemo sequential treatment.</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Inclusion criteria Pathologically confirmed to be rectal adenocarcinoma. Distance &lt; 10cm from the end of the tumor to the anal verge found on colonoscopy Tumor in stage T34N02 (pelvic MRI evaluation) Patients without distant metastases (such as liver and peritoneum, lungs, aortic lymph nodes) Patients with Karnofsky score greater â‰¥ 70 WBC &gt; 3.5 x 109/ml , PLT &gt; 10 x 109/ml , TBIL&lt;22.2 umol/l , BUN &lt;7.14mmol/l , Cr&lt;132umol/l or Ccr &gt; 50ml/min (Evaluated using the CockcroftGault formula: Creatinine clearance (male) = {(140 age) x LBM (kg)} / {plasma creatinine (mg/dl) x 72} ; Creatinine clearance (female) = 0.85 x {(140 age) x LBM(kg)}/ { plasma creatinine (mg/dl) x 72}) Patients must sign the informed consent form Female subjects must be contraceptive during the trial Patients who did not receive any form of chemotherapy and radiotherapy No other important related diseases (such as other tumors, severe heart disease and central nervous system diseases, etc.) Age must be equal or more than 20 and must be equal or less than 70 Exclusion criteria Previously received radiation therapy, chemotherapy or antitumor biological therapy Previously received immunosuppressive therapy Participation in interventional clinical trial over the past time Suffering from malignant colonic neoplasms simultaneously With peripheral neuropathy(above WHO I level) Affected cognitive abilities because of neurological or psychiatric abnormalities Including central nervous system metastasis Medical history of severe allergies or allergic constitution Severe pulmonary or heart disease history Female patients who are in pregnancy or lactation and refuse contraception Previously with other malignant tumors Exit criteria Occurrence of bleeding, obstruction, perforation and other complications Occurrence of distant metastasis during the period of neoadjuvant therapy Adverse reactions, not be tolerated and do not want to continue to receive treatment Patients voluntarily quit Capecitabinerelated Grade 4 HandFoot Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoadjuvant Chemotherapy</keyword>
</DOC>